CG Oncology News

Goldman Sachs Upgrades CG Oncology to Buy From Neutral With $50 Price Target

MT NewswiresMay 14 07:53 ET

CG Oncology Analyst Ratings

BenzingaMay 13 16:23 ET

CG Oncology Analyst Ratings

BenzingaMay 10 08:26 ET

CG Oncology Analyst Ratings

BenzingaMay 6 06:48 ET

CG Oncology's Cretostimogene Shows Promising Efficacy and Safety in NMIBC Treatment, Merits Buy Rating

TipRanksMay 6 06:16 ET

Buy Rating Justified by CG Oncology's Cretosmogene Efficacy and Market Positioning

TipRanksMay 3 15:15 ET

CG Oncology Analyst Ratings

BenzingaMay 2 11:59 ET

Buy Rating Affirmed for CG Oncology Amidst Bladder Cancer Treatment Landscape and BCG Shortage

TipRanksApr 23 08:25 ET

Buy Rating Affirmed for CG Oncology on Strong Clinical Data and Market Potential

TipRanksApr 4 06:15 ET

CG Oncology Analyst Ratings

BenzingaApr 4 06:08 ET

Buy Rating Justified by CG Oncology's Strong Clinical Trial Results and Promising Cretosimogene Therapy

TipRanksApr 1 07:36 ET

Buy Rating Affirmed for CG Oncology, Inc. on Promising CG0070 Phase 3 Trials and Unmet Medical Need

TipRanksFeb 27 19:35 ET

CG Oncology's CG0070: A Buy Rating on Breakthrough Bladder Cancer Treatment

TipRanksFeb 20 06:45 ET

CG Oncology Analyst Ratings

BenzingaFeb 20 05:25 ET

Buy Rating Affirmed for CG Oncology on Cretostimogene's Clinical Success and Market Potential

TipRanksFeb 19 19:15 ET

CG Oncology Analyst Ratings

BenzingaFeb 14 06:53 ET